STEP THERAPY CRITERIA

This list is current as of 06/01/2019 and pertains to the following formularies:

| 2019 Independent Health’s Assure AdvantageSM (HMO-SNP) Part D Formulary | Version 21 |

In some cases, we require that you first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. This document contains the Step Therapy protocols that are associated with our Medicare Advantage Part D Formularies.

If you have any questions, please contact our Medicare Member Services Department at 1-800-665-1502 or, for TTY users 711, October 1st – March 31st: Monday through Sunday from 8 a.m. to 8 p.m., April 1st – September 30th: Monday through Friday from 8 a.m. to 8 p.m.

Independent Health is a Medicare Advantage organization with a Medicare contract offering HMO, HMO-SNP, HMO-POS and PPO plans. Enrollment in Independent Health depends on contract renewal.

The formulary may change at any time. You will receive notice when necessary.
### Aliskiren Step

#### Products Affected

- aliskiren fumarate tablet 150 mg oral
- aliskiren fumarate tablet 300 mg oral
- TEKTURNA HCT TABLET 150-12.5 MG ORAL
- TEKTURNA HCT TABLET 150-25 MG ORAL
- TEKTURNA TABLET 150 MG ORAL
- TEKTURNA TABLET 300 MG ORAL

#### Details

#### Criteria

| Criteria | Prior prescription history of an ARB to obtain any products containing aliskiren. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
# Doxercalciferol Step

## Products Affected
- doxercalciferol capsule 0.5 mcg oral
- doxercalciferol capsule 1 mcg oral
- doxercalciferol capsule 2.5 mcg oral

## Details

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Prior prescription history includes past use of calcitriol.</th>
</tr>
</thead>
</table>

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
## GLP-1 Step

### Products Affected

- BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS
- BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS
- BYDUREON SUSPENSION REconstituted ER 2 MG SUBCUTANEOUS
- BYETTA 10 MCG PEN SOLUTION PEN-INJECTOR 10 MCG/0.04ML SUBCUTANEOUS
- BYETTA 5 MCG PEN SOLUTION PEN-INJECTOR 5 MCG/0.02ML SUBCUTANEOUS
- OZEMPIC SOLUTION PEN-INJECTOR 0.25 OR 0.5 MG/DOSE SUBCUTANEOUS
- OZEMPIC SOLUTION PEN-INJECTOR 1 MG/DOSE SUBCUTANEOUS
- TANZEUM PEN-INJECTOR 30 MG SUBCUTANEOUS
- TANZEUM PEN-INJECTOR 50 MG SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS
- VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS

### Details

<table>
<thead>
<tr>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior prescription history includes concurrent use of metformin, a sulfonylurea, a DPP-4, or a TZD before a GLP-1 agonist. Step therapy does not apply when written by endocrinologist.</td>
</tr>
</tbody>
</table>

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
### Glyxambi Step

**Products Affected**
- GLYXAMBI TABLET 10-5 MG ORAL
- GLYXAMBI TABLET 25-5 MG ORAL

**Details**

| Criteria | Requires either linagliptan or empagliflozin prior to use. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
# Mirvaso Step

## Products Affected
- MIRVASO GEL 0.33 % EXTERNAL

## Details

| Criteria                        | Prior prescription history positive for the use of azelaic acid. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Nexium Packet Step

Products Affected
• NEXIUM PACKET 10 MG ORAL
• NEXIUM PACKET 2.5 MG ORAL
• NEXIUM PACKET 20 MG ORAL
• NEXIUM PACKET 40 MG ORAL
• NEXIUM PACKET 5 MG ORAL

Details

| Criteria | Prior prescription history includes use of omeprazole or pantoprazole except for NSAID-induced gastric ulcer prophylaxis or treatment. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Paricalcitol/Rayaldee Step

Products Affected
- paricalcitol capsule 1 mcg oral
- paricalcitol capsule 2 mcg oral
- paricalcitol capsule 4 mcg oral
- RAYALDEE CAPSULE EXTENDED RELEASE 30 MCG ORAL

Details

| Criteria | Prior prescription history includes past use of calcitriol. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
## Tramadol ER Biphasic Step

### Products Affected

- tramadol hcl er (biphasic) tablet extended release 24 hour 100 mg oral
- tramadol hcl er (biphasic) tablet extended release 24 hour 200 mg oral
- tramadol hcl er (biphasic) tablet extended release 24 hour 300 mg oral
- tramadol hcl er capsule extended release 24 hour 150 mg oral
- tramadol hcl er capsule extended release 24 hour 200 mg oral
- tramadol hcl er capsule extended release 24 hour 300 mg oral

### Details

| Criteria | Requires the use of an immediate-release tramadol product or non-biphasic extended-release tramadol first. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
INDEX

aliskiren fumarate tablet 150 mg oral........... 1
aliskiren fumarate tablet 300 mg oral........... 1
BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS........................ 3
BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS.............................................3
BYDUREON SUSPENSION RECONSTITUTED ER 2 MG SUBCUTANEOUS.................... 3
BYETTA 10 MCG PEN SOLUTION PEN-INJECTOR 10 MCG/0.04ML
SUBCUTANEOUS.......................................................... 3
BYETTA 5 MCG PEN SOLUTION PEN-INJECTOR 5 MCG/0.02ML SUBCUTANEOUS...3
doxercalciferol capsule 0.5 mcg oral.............. 2
doxercalciferol capsule 1 mcg oral............... 2
doxercalciferol capsule 2.5 mcg oral............ 2
GLYXAMBI TABLET 10-5 MG ORAL................. 4
GLYXAMBI TABLET 25-5 MG ORAL................. 4
MIRVASO GEL 0.33 % EXTERNAL.................... 5
NEXIUM PACKET 10 MG ORAL....................... 6
NEXIUM PACKET 2.5 MG ORAL...................... 6
NEXIUM PACKET 20 MG ORAL...................... 6
NEXIUM PACKET 40 MG ORAL...................... 6
NEXIUM PACKET 5 MG ORAL....................... 6
OZEMPIC SOLUTION PEN-INJECTOR 0.25 OR 0.5 MG/DOSE SUBCUTANEOUS........3
OZEMPIC SOLUTION PEN-INJECTOR 1 MG/DOSE SUBCUTANEOUS...................... 3
paricalcitol capsule 1 mcg oral................... 7
paricalcitol capsule 2 mcg oral................... 7
paricalcitol capsule 4 mcg oral................... 7
RAYALDEE CAPSULE EXTENDED RELEASE
30 MCG ORAL.......................................................... 7
TANZEUM PEN-INJECTOR 30 MG SUBCUTANEOUS.............................................3
TANZEUM PEN-INJECTOR 50 MG SUBCUTANEOUS.............................................3
TEKTURNA HCT TABLET 150-12.5 MG ORAL.. 1
TEKTURNA HCT TABLET 150-25 MG ORAL.... 1
TEKTURNA HCT TABLET 300-12.5 MG ORAL.. 1
TEKTURNA HCT TABLET 300-25 MG ORAL.... 1
TEKTURNA TABLET 150 MG ORAL............... 1
TEKTURNA TABLET 300 MG ORAL............... 1
tramadol hcl er (biphasic) tablet extended release 24 hour 100 mg oral............... 8
tramadol hcl er (biphasic) tablet extended release 24 hour 200 mg oral............... 8
tramadol hcl er (biphasic) tablet extended release 24 hour 300 mg oral............... 8
tramadol hcl er capsule extended release 24 hour 100 mg oral....................... 8
tramadol hcl er capsule extended release 24 hour 150 mg oral....................... 8
tramadol hcl er capsule extended release 24 hour 200 mg oral....................... 8
TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS................. 3
TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS..................... 3
VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS.......................... 3